23 related articles for article (PubMed ID: 21944124)
1. A form of circulating interleukin-6 receptor component soluble gp130 as a potential interleukin-6 inhibitor in inflammatory bowel disease.
Mitsuyama K; Tomiyasu N; Suzuki A; Takaki K; Takedatsu H; Masuda J; Yamasaki H; Matsumoto S; Tsuruta O; Toyonaga A; Sata M
Clin Exp Immunol; 2006 Jan; 143(1):125-31. PubMed ID: 16367943
[TBL] [Abstract][Full Text] [Related]
2. Drosophila Jak/STAT Signaling: Regulation and Relevance in Human Cancer and Metastasis.
Trivedi S; Starz-Gaiano M
Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30558204
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-6 and Interferon-α Signaling
Danziger O; Pupko T; Bacharach E; Ehrlich M
Front Immunol; 2018; 9():94. PubMed ID: 29441069
[TBL] [Abstract][Full Text] [Related]
4. Diacerein-mediated inhibition of IL-6/IL-6R signaling induces apoptotic effects on breast cancer.
Bharti R; Dey G; Ojha PK; Rajput S; Jaganathan SK; Sen R; Mandal M
Oncogene; 2016 Jul; 35(30):3965-75. PubMed ID: 26616855
[TBL] [Abstract][Full Text] [Related]
5. SPINK1 Promoter Variants Are Associated with Prostate Cancer Predisposing Alterations in Benign Prostatic Hyperplasia Patients.
Winchester D; Ricks-Santi L; Mason T; Abbas M; Copeland RL; Beyene D; Jingwi EY; Dunston GM; Kanaan YM
Anticancer Res; 2015 Jul; 35(7):3811-9. PubMed ID: 26124326
[TBL] [Abstract][Full Text] [Related]
6. The proinflammatory cytokine, IL-6, and its interference with bFGF signaling and PSMA in prostate cancer cells.
Ben Jemaa A; Sallami S; Ramarli D; Colombatti M; Oueslati R
Inflammation; 2013 Jun; 36(3):643-50. PubMed ID: 23250823
[TBL] [Abstract][Full Text] [Related]
7. IL-6/IL-6R as a potential key signaling pathway in prostate cancer development.
Azevedo A; Cunha V; Teixeira AL; Medeiros R
World J Clin Oncol; 2011 Dec; 2(12):384-96. PubMed ID: 22171281
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of lymphovascular invasion in radical prostatectomy specimens.
Yee DS; Shariat SF; Lowrance WT; Maschino AC; Savage CJ; Cronin AM; Scardino PT; Eastham JA
BJU Int; 2011 Aug; 108(4):502-7. PubMed ID: 21050364
[TBL] [Abstract][Full Text] [Related]
9. Soluble gp130 regulates prostate cancer invasion and progression in an interleukin-6 dependent and independent manner.
Shariat SF; Chromecki TF; Hoefer J; Barbieri CE; Scherr DS; Karakiewicz PI; Roehrborn CG; Montorsi F; Culig Z; Cavarretta IT
J Urol; 2011 Nov; 186(5):2107-14. PubMed ID: 21944124
[TBL] [Abstract][Full Text] [Related]
10. Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis.
Shariat SF; Andrews B; Kattan MW; Kim J; Wheeler TM; Slawin KM
Urology; 2001 Dec; 58(6):1008-15. PubMed ID: 11744478
[TBL] [Abstract][Full Text] [Related]
11. Association of pre- and postoperative plasma levels of transforming growth factor beta(1) and interleukin 6 and its soluble receptor with prostate cancer progression.
Shariat SF; Kattan MW; Traxel E; Andrews B; Zhu K; Wheeler TM; Slawin KM
Clin Cancer Res; 2004 Mar; 10(6):1992-9. PubMed ID: 15041717
[TBL] [Abstract][Full Text] [Related]
12. Association of preoperative plasma levels of insulin-like growth factor I and insulin-like growth factor binding proteins-2 and -3 with prostate cancer invasion, progression, and metastasis.
Shariat SF; Lamb DJ; Kattan MW; Nguyen C; Kim J; Beck J; Wheeler TM; Slawin KM
J Clin Oncol; 2002 Feb; 20(3):833-41. PubMed ID: 11821468
[TBL] [Abstract][Full Text] [Related]
13. Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis.
Shariat SF; Roehrborn CG; McConnell JD; Park S; Alam N; Wheeler TM; Slawin KM
J Clin Oncol; 2007 Feb; 25(4):349-55. PubMed ID: 17264329
[TBL] [Abstract][Full Text] [Related]
14. What are the factors associated with short prostate specific antigen doubling time after radical prostatectomy? A report from the SEARCH database group.
Teeter AE; Bañez LL; Presti JC; Aronson WJ; Terris MK; Kane CJ; Amling CL; Freedland SJ;
J Urol; 2008 Nov; 180(5):1980-4; discussion 1985. PubMed ID: 18801519
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
